Spot Ex PMCF 01 Study
NCT07206615 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60
Last updated 2026-08-25
Summary
Post market clinical study that is a chart review of the Spot Ex Endoscopic Marker
Conditions
- Presence of Spot Ex Endoscopic Marker
Interventions
- OTHER
-
Endoscopic marker
Study to confirm the safety and performance of the Laborie Spot Ex Endoscopic Marker in accordance with the approved labelling/instructions for use (IFU).
Sponsors & Collaborators
-
Laborie Medical Technologies Inc.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-10-01
- Primary Completion
- 2026-08-21
- Completion
- 2026-08-21
Countries
- United States
Study Locations
More Related Trials
-
A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation
NCT02875366 ·Status: COMPLETED ·Phase: PHASE4
-
FDG-PET Imaging in Young Cystic Fibrosis Patients
NCT00846053 ·Status: COMPLETED ·Phase: NA
-
A CFit Study - Acute Exercise
NCT03237767 ·Status: TERMINATED ·Phase: NA
-
Pharmacokinetics of Polymyxin B in Adult Patients With Cystic Fibrosis
NCT04335370 ·Status: COMPLETED
-
Elastography of the Liver in Cystic Fibrosis Patients. Diagnostic and Prognostic Aspects
NCT02603666 ·Status: COMPLETED ·Phase: NA
-
Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency
NCT00449878 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 1, QT/QTC Interval Study in Healthy Subjects
NCT01910415 ·Status: COMPLETED ·Phase: PHASE1
-
Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis
NCT03140527 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy Study of IgY (Antibody Against Pseudomonas) in Cystic Fibrosis Patients
NCT01455675 ·Status: COMPLETED ·Phase: PHASE3
-
Hyperpolarized Xenon MRI in Cystic Fibrosis Pulmonary Exacerbations
NCT02606487 ·Status: COMPLETED
-
MRI in Cystic Fibrosis and Primary Ciliary Dyskinesia
NCT03279965 ·Status: UNKNOWN
-
Exocrine Pancreatic Function Testing in Cystic Fibrosis
NCT01446861 ·Status: UNKNOWN
-
An Open-Label, Phase 1 Study in Healthy Adult Subjects to Examine the Effects of Multiple-Dose Ciprofloxacin on Ivacaftor and VX-661 in Combination With Ivacaftor
NCT02015507 ·Status: COMPLETED ·Phase: PHASE1
-
18FDG-PET Imaging to Detect Changes in Airways Inflammation in Cystic Fibrosis Patients
NCT00684346 ·Status: COMPLETED ·Phase: PHASE3
-
Role of Body Fat Distribution in Metabolic and Pulmonary Decline in Cystic Fibrosis (ORBIT-CF)
NCT04002882 ·Status: RECRUITING
-
Pro-resolving Effect of MAG-DHA in Cystic Fibrosis (PREMDIC)
NCT02518672 ·Status: TERMINATED ·Phase: PHASE2
-
The Role of Bacteria and Genetic Variations in Cystic Fibrosis
NCT00043225 ·Status: COMPLETED
-
Assessment of CFTR-Modulator Treatment in Cystic Fibrosis Lung Disease Using Novel Structural and Functional MRI
NCT04391322 ·Status: ACTIVE_NOT_RECRUITING
-
Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients
NCT02178540 ·Status: COMPLETED ·Phase: PHASE4
-
Sputum Purulence as a Predictor of Cystic Fibrosis Exacerbations: a Prospective Cohort Trial.
NCT02309229 ·Status: COMPLETED
-
Outpatient Antibiotic Treatment for a Cystic Fibrosis Pulmonary Exacerbation
NCT02480270 ·Status: COMPLETED
-
A CFit Study - Baseline
NCT03234387 ·Status: TERMINATED
-
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
NCT03566550 ·Status: COMPLETED
-
Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)
NCT01614457 ·Status: COMPLETED ·Phase: PHASE3
-
PREDICT Trial: PRospective Evaluation of NTM Disease In CysTic Fibrosis
NCT02073409 ·Status: ENROLLING_BY_INVITATION